FGFR3 V555M
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FGFR3
Variant V555M
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions FGFR3 V555M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V555M results in increased Fgfr3 autophosphorylation and substrate phosphorylation in cell culture (PMID: 26992226), and is associated with resistance to Fgfr inhibitors in culture (PMID: 28034880).
Associated Drug Resistance Y
Category Variants Paths

FGFR3 mutant FGFR3 act mut FGFR3 V555M

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_000142.5
gDNA chr4:g.1805767G>A
cDNA c.1663G>A
Protein p.V555M
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_000142.4 chr4:g.1805767G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_006713873.2 chr4:g.1805767G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_006713871.1 chr4:g.1805761G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
NM_001163213.2 chr4:g.1805761G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_006713871 chr4:g.1805761G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_011513420.2 chr4:g.1805761G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_006713873 chr4:g.1805767G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
NM_000142 chr4:g.1805767G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_006713871.2 chr4:g.1805761G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
NM_001163213.1 chr4:g.1805761G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_047449823.1 chr4:g.1805767G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
NM_001163213 chr4:g.1805761G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_011513420.1 chr4:g.1805761G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_011513420 chr4:g.1805761G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
NM_000142.5 chr4:g.1805767G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_006713873.1 chr4:g.1805767G>A c.1663G>A p.V555M RefSeq GRCh38/hg38
XM_047449824.1 chr4:g.1805767G>A c.1663G>A p.V555M RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR3 V555M Advanced Solid Tumor resistant Infigratinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to Truseltiq (infigratinib) in culture (PMID: 28034880). 28034880
FGFR3 V555M Advanced Solid Tumor sensitive Ponatinib Preclinical - Cell culture Actionable In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880). 28034880
FGFR3 V555M Advanced Solid Tumor sensitive Dovitinib Preclinical - Cell culture Actionable In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880). 28034880
FGFR3 V555M Advanced Solid Tumor resistant Fexagratinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to Fexagratinib (AZD4547) in culture (PMID: 28034880). 28034880
FGFR3 V555M Advanced Solid Tumor decreased response Zoligratinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880). 28034880
FGFR3 V555M Advanced Solid Tumor decreased response FIIN-2 Preclinical - Cell culture Actionable In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880). 28034880
FGFR3 V555M Advanced Solid Tumor sensitive LY2874455 Preclinical - Cell culture Actionable In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880). 28034880
FGFR3 V555M transitional cell carcinoma resistant Infigratinib Case Reports/Case Series Actionable In a clinical study, a patient with metastatic urothelial carcinoma progressed while being treated with Truseltiq (infigratinib) and subsequent cell-free DNA testing revealed FGFR3 V555M (also corresponds to V443M) (PMID: 29848605). 29848605
FGFR3 V555M Advanced Solid Tumor resistant Pemigatinib Preclinical - Cell culture Actionable In a preclinical study, a cell line expressing FGFR3 V555M was resistant to Pemazyre (pemigatinib) in a kinase assay and in culture (PMID: 36698015). 36698015